Precigen Q1 2020 Earnings Report
Key Takeaways
Precigen reported total revenues of $29.8 million and a net loss from continuing operations attributable to Precigen of $29.9 million, or $(0.19) per basic share. Cash, cash equivalents, and short-term investments totaled $149.2 million at March 31, 2020.
Received FDA clearance of PRGN-2009 to initiate a Phase 1/2 trial in HPV-positive solid tumors.
Dosing in the second dose level of the intraperitoneal (IP) arm of the Phase 1 trial of PRGN-3005 UltraCAR-T was completed.
Enrollment of patients in the non-lymphodepletion and lymphodepletion arms of the Phase 1 trial of PRGN-3006 UltraCAR-T has been unaffected by the COVID-19 pandemic to date.
MBP Titan LLC significantly reduced its resource requirements through a workforce reduction.
Precigen
Precigen
Precigen Revenue by Segment
Forward Guidance
Precigen maintains guidance for clinical readouts in 2020.
Revenue & Expenses
Visualization of income flow from segment revenue to net income